These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 17219666)

  • 1. Anti-HIV agents. Low rate of early virologic failure seen with a combination of Trizivir and tenofovir.
    TreatmentUpdate; 2004 Mar; 16(2):2-3. PubMed ID: 17219666
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term follow-up of patients with initial early virologic failure after being treated with once-daily tenofovir/abacavir/lamivudine.
    Khanlou H; Farthing C
    AIDS Patient Care STDS; 2006 Sep; 20(9):604-5. PubMed ID: 16987045
    [No Abstract]   [Full Text] [Related]  

  • 3. Failure of tenofovir + abacavir + 3TC combination; full report published, more insight.
    James JS
    AIDS Treat News; 2005; (416):5-6. PubMed ID: 16388545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abacavir/3TC vs. tenofovir/FTC: interim results from ACTG 5202.
    Albrecht H
    AIDS Clin Care; 2008 Apr; 20(4):28. PubMed ID: 19271262
    [No Abstract]   [Full Text] [Related]  

  • 5. Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only?
    Stephan C; Dauer B; Khaykin P; Stuermer M; Gute P; Klauke S; Staszewski S
    Curr HIV Res; 2009 May; 7(3):320-6. PubMed ID: 19442129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virologic response of zidovudine, lamivudine, and tenofovir disoproxil fumarate combination in antiretroviral-naive HIV-1-infected patients.
    Rey D; Krebs M; Partisani M; Hess G; Cheneau C; Priester M; Bernard-Henry C; de Mautort E; Lang JM
    J Acquir Immune Defic Syndr; 2006 Dec; 43(5):530-4. PubMed ID: 17057610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simplified maintenance therapy with abacavir/lamivudine/zidovudine plus tenofovir after sustained HIV load suppression: four years of follow-up.
    d'Ettorre G; Zaffiri L; Ceccarelli G; Andreotti M; Massetti AP; Vella S; Mastroianni CM; Vullo V
    HIV Clin Trials; 2007; 8(3):182-8. PubMed ID: 17621465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-daily abacavir/lamivudine/zidovudine plus tenofovir for the treatment of HIV-1 infection in antiretroviral-naïve subjects: a 48-week pilot study.
    Elion R; Cohen C; DeJesus E; Redfield R; Gathe J; Hsu R; Yau L; Ross L; Ha B; Lanier RE; Scott T;
    HIV Clin Trials; 2006; 7(6):324-33. PubMed ID: 17208898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
    Manfredi R; Calza L
    AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202.
    Grant PM; Tierney C; Budhathoki C; Daar ES; Sax PE; Collier AC; Fischl MA; Zolopa AR; Balamane M; Katzenstein D
    HIV Clin Trials; 2013; 14(6):284-91. PubMed ID: 24334181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence to trizivir and tenofovir as a simplified salvage regimen is associated with suppression of viraemia and a decreased cholesterol.
    Latham V; Stebbing J; Mandalia S; Michailidis C; Davies E; Bower M; Gazzard B; Nelson M
    J Antimicrob Chemother; 2005 Jul; 56(1):186-9. PubMed ID: 15911551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. We want our Trizivir!
    Vázquez E
    Posit Aware; 2003; 14(5):25-6. PubMed ID: 14679938
    [No Abstract]   [Full Text] [Related]  

  • 13. Zidovudine/lamivudine/abacavir plus tenofovir in HIV-infected naive patients: a 96-week prospective one-arm pilot study.
    Ferrer E; Gatell JM; Sanchez P; Domingo P; Puig T; Niubo J; Cortes C; Veloso S; Pedrol E; Leon A; Gutierrez M; Podzamczer D
    AIDS Res Hum Retroviruses; 2008 Jul; 24(7):931-4. PubMed ID: 18671476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-HIV agents. Trying times for tenofovir and abacavir.
    TreatmentUpdate; 2003 Oct; 15(6):2-3. PubMed ID: 17216860
    [No Abstract]   [Full Text] [Related]  

  • 15. The absence of HIV mutations in cerebrospinal fluid and in peripheral blood mononuclear cells during a regimen containing Trizivir plus tenofovir.
    d'Ettorre G; Ceccarelli G; Turriziani O; Andreotti M; Massetti P; Rizza C; Vella S; Antonelli G; Mastroianni CM; Vullo V
    J Chemother; 2009 Aug; 21(4):455-7. PubMed ID: 19622468
    [No Abstract]   [Full Text] [Related]  

  • 16. Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40263).
    Ross L; Elion R; Lanier R; Dejesus E; Cohen C; Redfield RR; Gathe JC; Hsu RK; Yau L; Paulsen D; Ha B;
    AIDS Res Hum Retroviruses; 2009 Jul; 25(7):665-72. PubMed ID: 19563238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigating new antiretroviral combinations.
    Carr A
    J Infect Dis; 2006 Jun; 193(12):1742; author reply 1742-3. PubMed ID: 16703520
    [No Abstract]   [Full Text] [Related]  

  • 18. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.
    Pozniak AL; Gallant JE; DeJesus E; Arribas JR; Gazzard B; Campo RE; Chen SS; McColl D; Enejosa J; Toole JJ; Cheng AK
    J Acquir Immune Defic Syndr; 2006 Dec; 43(5):535-40. PubMed ID: 17057609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Suboptimal response to once-daily abacavir + 3TC + tenofovir.
    Feinberg J
    AIDS Clin Care; 2003 Nov; 15(11):94. PubMed ID: 14682272
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of abacavir/lamivudine and tenofovir/emtricitabine among treatment-naive HIV-infected patients initiating therapy.
    Tan DH; Chan K; Raboud J; Cooper C; Montaner JS; Walmsley S; Hogg RS; Klein MB; Machouf N; Rourke SB; Tsoukas C; Loutfy MR;
    J Acquir Immune Defic Syndr; 2011 Sep; 58(1):38-46. PubMed ID: 21709570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.